Racura Oncology Ltd · ASX:RAC
Racura Oncology — Race Oncology — 11th Annual Australian Microcap Investment Conference 2022
28 slides from Racura Oncology's conference presentation, Oct 18, 2022
Slide 1: ASX Announcement: Investor presentation for Australian Microcap Conference
ASX Announcement Investor presentation for Australian Microcap Conference For personal use only 18 October 2022 – Race Oncology Limited (“Race”) is pleased to release a copy of the presentation that will be delivered to investors today at the 11th Annual Australian Microcap Investment Conference, an
Slide 2: Release authorisation and media contact
Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au For personal use only Release authorised by: Media contact: Phil Lynch, CEO/MD on behalf Jane Lowe of the Race Board of Directors +61 41
Slide 3: RNA-Directed Therapeutics to Treat Cancer and Protect the Heart
For personal use only RNA-DIRECTED THERAPEUTICS TO TREAT CANCER AND PROTECT THE HEART Investor Update October 2022 RACE ONCOLOGY LIMITED (ASX:RAC) 1 INVESTOR PRESENTATION
Slide 4: Disclaimer
DISCLAIMER For personal use only Investment in Race Oncology (Race) is subject to investment risk, including possible loss of income and capital invested. Race does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an
Slide 5: 2020-2022 A Pivotal Period for Zantrene
2020-2022 A PIVOTAL PERIOD FOR ZANTRENE June 2020 March 2021 September 2021 December 2021 April 2022 June 2022 September 2022 For personal use only Impressive 40% Multiple pre-clinical Preclinical results Zantrene found to protect Human ethics Melanoma preclinical Race develops response in Phase FTO
Slide 6: Corporate Snapshot
CORPORATE SNAPSHOT For personal use only ISSUED CAPITAL ASX 24 MONTH PERFORMANCE Shares1 158.9m Options1 13.4m Shareholders2 9,302 MARKET CAPITALISATION Share price1 $2.20 Market value1 $349.6m Cash2 $33.5m Enterprise value $316.1m SIGNIFICANT SHAREHOLDERS Dr Daniel Tillett (Director & CSO) 8.6% Dr
Slide 7: Why Invest in Race Oncology Now?
WHY INVEST IN RACE ONCOLOGY NOW? For personal use only Race is the first Independent Extensive clinical Robust and company in the opportunity for history that derisks growing IP clinic targeting the Zantrene preventing clinical development from improved m6A RNA (FTO) heart damage caused formulation
Slide 8: Three Heroes
THREE HEROES For personal use only 1 The drug 2 The team 3 The three pillar strategy RACE ONCOLOGY LIMITED (ASX:RAC) 6 INVESTOR PRESENTATION
Slide 9: The Drug. History
THE DRUG. HISTORY For personal use only Zantrene (bisantrene) Derisked by extensive prior clinical development as an anthracycline alternative > 1500 patients > 50 clinical trials > Received US Orphan Drug designation (7 years exclusivity) > Successfully manufactured the GMP drug > 6 issued US paten
Slide 10: The Drug. Today
THE DRUG. TODAY Zantrene sits across several hot areas of cancer research For personal use only Zantrene can 1. Inhibit FTO. Leukaemias, solid tumours, immune checkpoint therapy resistance 2. Provide cardioprotection together with improved anti-cancer activity RACE ONCOLOGY LIMITED (ASX:RAC) 8 INVES
Slide 11: The Team: Seasoned Board and Executive
THE TEAM: SEASONED BOARD AND EXECUTIVE For personal use only BOARD Dr John Cullity, Mr Phil Lynch, Dr Daniel Tillett, Mary Harney Non-Executive Chairman CEO and Managing Director CSO and Executive Director Non-Executive Director MANAGEMENT Mr Phil Lynch, Dr Daniel Tillett, PhD Dr David Fuller Dr Mar
Slide 12: Building Shareholder Value. Three Pillar Strategy
BUILDING SHAREHOLDER VALUE. THREE PILLAR STRATEGY Three derisked pillars with new formulations & new IP. For personal use only Develop each program to proof of concept for pharma partnership/transaction ZANTRENE® ZANTRENE® BEYOND 1 2 OPTIMISED 3 ZANTRENE® Maximising Current Enhancing Zantrene® Utili
Slide 13: Expanded Pipeline
EXPANDED PIPELINE TARGETING m6A RNA METHYLATION (FTO) & CARDIO-PROTECTION For personal use only PRECLINICAL CLINICAL DISCOVERY IN VITRO IN VIVO PHASE I PHASE II REGISTRATION r/r AML (combination) Zantrene + fludarabine + clofarabine, Chaim Sheba Israel ZANTRENE® EMD AML (stratum 1) High Dose Zantren
Slide 14: Acute Myeloid Leukaemia
For personal use only ACUTE MYELOID LEUKAEMIA RACE ONCOLOGY LIMITED (ASX:RAC) 12 INVESTOR PRESENTATION
Slide 15: Zantrene Clinical Phase 1b/2 - R/R AML Status
1 ZANTRENE® CLINICAL PHASE 1B/2 - R/R AML STATUS For personal use only 2020 Phase 2 trial demonstrated an impressive 40% overall response rate for Zantrene as a single agent in R/R AML 1 CURRENT R/R AML PHASE 1B/2 TRIAL • Phase 1b/2 combination study in up to 29 R/R AML patients (NCT04989335) • Regi
Slide 16: FTO and RNA
For personal use only FTO AND RNA RACE ONCOLOGY LIMITED (ASX:RAC) 14 INVESTOR PRESENTATION
Slide 17: FTO. Central Role in Cancer
FTO. CENTRAL ROLE IN CANCER • Scientific discoveries over the last decade have identified For personal use only dysregulation (loss of control) of m6A RNA methylation as a key driver of cancer development and other disease1 • Changes in m6A RNA methylation control the expression of key genes in canc
Slide 18: Zantrene EMD AML. FTO Clinical Proof-of-Concept
1 ZANTRENE® EMD AML. FTO CLINICAL PROOF-OF-CONCEPT WHY EXTRAMEDULLARY (EMD) AML? For personal use only • High unmet medical need with no stand-of-care therapy • EMD prevalence > 20% AML patients1 with poor prognosis • Initial registrational path with likely FDA 505(b)(2) approval • Small number of p
Slide 19: Melanoma and Zantrene: Improving Immuno-Oncology Therapy
2 ZANTRENE® OPTIMISED MELANOMA & ZANTRENE IMPROVING IMMUNO-ONCOLOGY THERAPY For personal use only • One of the most lethal and treatment resistant cancers with 5-year survival rate for advanced melanoma around 25%1 • FTO is overexpressed in ~50% of all metastatic melanomas and inhibition of FTO over
Slide 20: Clear Cell Renal Cell Cancer
ZANTRENE® 2 OPTIMISED CLEAR CELL RENAL CELL CANCER For personal use only • 10th most common cancer with 12% 5-year survival rate1 • 90% of ccRCC have mutations in von Hippel-Lindau (VHL) tumour suppressor gene2 • Inhibition of FTO was found to kill VHL(-) ccRCC cancers3 RACE ONCOLOGY PROGRAM • Prof
Slide 21: Cardioprotection
For personal use only CARDIOPROTECTION RACE ONCOLOGY LIMITED (ASX:RAC) 19 INVESTOR PRESENTATION
Slide 22: Zantrene Anthracycline Cardioprotection
1 ZANTRENE® ANTHRACYCLINE CARDIOPROTECTION For personal use only • Heart damage from cancer therapies is a major and increasing issue as cancer patients live longer • Anthracyclines, anti-HER2, targeted agents and immuno- McGowan J et al Anthracycline Chemotherapy and Cardiotoxicity Cardiovasc Drugs
Slide 23: Zantrene Protects Hearts from Doxorubicin Cardiotoxicity
1 ZANTRENE® ZANTRENE PROTECTS HEARTS FROM DOXORUBICIN CARDIOTOXICITY For personal use only • Zantrene protects the hearts of mice from permanent damage caused by doxorubicin • Heart protection was achieved using higher levels of chemotherapy treatment with no extra general toxicity • Supports future
Slide 24: Other Recent News
For personal use only OTHER RECENT NEWS RACE ONCOLOGY LIMITED (ASX:RAC) 22 INVESTOR PRESENTATION
Slide 25: Zantrene Optimised: Improved IV Formulation
2 ZANTRENE® OPTIMISED IMPROVED IV FORMULATION EXTENDING AND ENHANCING ZANTRENE For personal use only Original Zantrene formulation requires a two hour central line IV infusion due to crystallisation in the blood Not optimal for use in patients with solid tumours (most cancers) Race has developed a n
Slide 26: New m6A RNA Targeting Molecules: Beyond Zantrene
NEW m6A RNA TARGETING MOLECULES BEYOND 3 ZANTRENE® For personal use only Recent scientific and clinical discoveries implicate m6A RNA methylation in many disease areas including cancer • Initiated NMR based drug screen program in collaboration with Monash Fragment Platform • Targeting FTO and other
Slide 27: Recent / Expected News
RECENT / EXPECTED NEWS CY 2022 For personal use only ✓ Zantrene IV formulation ✓ Collaboration with Monash University to develop new M6A RNA targeted drugs • IND submission plan – CY 2022 • Additional animal data – cardioprotection • Update on cardioprotection clinical trial plan • First patient dos
Slide 28: Contact us
For personal use only Contact us: Phil Lynch CEO & MD – phillip.lynch@raceoncology.com Dr Daniel Tillett CSO & Exec Director - daniel.tillett@raceoncology.com RACE ONCOLOGY LIMITED (ASX:RAC) 26 INVESTOR PRESENTATION
Race Oncology — 11th Annual Australian Microcap Investment Conference 2022 on 6ix